Table 1 Baseline patient and disease characteristics and treatment approach with SIRT according to the number of procedures with each application agent
Sterile water | Isotonic 5 % glucose (G5W) | p value* | |
|---|---|---|---|
Gender, n (%) | ns | ||
Male:female (procedure based) | 28:22 | 33:21 | |
Male:female (patient based) | 12:12 | 18:11 | |
Mean age, years | ns | ||
Procedure based | 61 | 65 | |
Patient based | 60.5 | 66 | |
Older than 65 years old, n (%) | ns | ||
Procedure based | 16 (32 %) | 25 (46.8 %) | |
Patient based | 7 (29 %) | 15 (52 %) | |
Primary tumor origin, n (%) | |||
Procedure based | |||
Colorectal cancer | 15 | 14 | ns |
Hepatocellular carcinoma | 11 | 14 | |
Neuroendocrine tumor | 9 | 13 | |
Breast cancer | 9 | 7 | |
Cholangiocarcinoma | 4 | 2 | |
Others | 2 | 4 | |
Patient based | |||
Colorectal cancer | 5 | 7 | |
Hepatocellular carcinoma | 6 | 7 | |
Neuroendocrine tumor | 4 | 8 | |
Breast cancer | 4 | 2 | |
Cholangiocarcinoma | 3 | 1 | |
Others | 2 | 4 | |
Prior TACE | 6 | 9 | ns |
Activity planned GBq, median (range) | ns | ||
Procedure based | 1.54 GBq (0.5–2.5) | 1.45 GBq (0.5–2.4) | |
Patient based | 1.5 (0.56–2.1) | 1.4 (0.6–2.4) | |
Activity delivered GBq, median (range) | |||
Procedure based | 1.05 (0.2–2.29) | 1.2 (0.3–2.4) | 0.04 |
Patient based | 1.0 (0.4–2.1) | 1.4 (0.6–2.4) | 0.005 |
Treatment approach, n (%) | ns | ||
Whole-liver treatment | 11 | 8 | |
Lobar | 38 | 43 | |
Segmental | 1 | 3 |